Retina

Latest News


CME Content


Patients who are currently hospitalized overnight for vitreoretinal surgery could safely be treated as day cases, thus providing significant improvements in efficiency, according to a report published in the February issue of Eye.

According to a presentation at the All India Ophthalmological Society meeting, when used appropriately, bevacizumab can produce remarkable results in children with severe retinopathy of prematurity (ROP).

The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina.

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

Sirion Therapeutics has entered into an exclusive agreement with Bridge Pharma for the worldwide rights to develop and market topical ophthalmic formulations containing Bridge's proprietary anti-inflammatory agent norketotifen.

It is recommended that all babies with retinopathy of prematurity (ROP) be screened at 12 months to identify amblyogenic factors such as squint and refractive error.

Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.

Systematic screening for diabetic retinopathy (DR) has been identified as a cost-effective use of health service resources,1-4 with national screening programmes based on digital photography being implemented across Europe. In Scotland, images are captured at local screening centres and sent electronically to one of nine regional grading centres, where they are manually graded using a three-level system (Figure 1).

New developments in diagnostic technology should enable better screening and follow-up of refractive surgery patients, said Dan Z. Reinstein, MD, delivering a keynote address during the refractive surgery subspecialty day preceding the annual meeting of the American Academy of Ophthalmology in November 2007.

The side effects and complications associated with intravitreal bevacizumab (Avastin) are minimal and can be prevented, in most cases, by careful injection and good patient selection.

The da Vinci Surgical System (Intuitive Surgical) provides adequate dexterity for performing delicate intraocular manipulation, however, the kinematics of the robotic arms is insufficient for standard intraocular surgery.

A study published online ahead of print by Diabetes Care has found that plasma total homocysteine concentration may be a useful biomarker and/or a novel risk factor for increased risk of diabetic retinopathy (DR) in people with type 2 diabetes.

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events.

Progress in the diagnosis and treatment of retinoblastoma has been minimal over the past couple of decades, although improvements have been made, and new therapies are being studied, according to an ocular oncology expert.

A Danish study published in the January issue of Pediatrics has found that the incidence of retinopathy of prematurity (ROP) treatment in Denmark has more than doubled during the past five years.

Intravitreal bevacizumab (Avastin; Genentech) appears to be a safe and effective treatment in the management of refractory inflammatory cystoid macular oedema.